A large European bank has quietly added to its stake in a young biotechnology company, a small but telling move made at a moment when that company's shares have fallen far from their peak. Deutsche Bank's purchase of more than eighty thousand shares in the first quarter, disclosed through a routine regulatory filing, sits among similar accumulations by pension funds, asset managers and other institutions, even as the stock trades near twenty-two dollars and recent earnings came in worse than expected. The picture is one of patient capital weighing a long scientific bet against a discouraging s
Deutsche Bank Lifts Vera Therapeutics Stake 10.2% to 892,859 Shares
Deutsche Bank was not the only institution moving.
Mark
Deutsche Bank bought more Vera shares. How big a deal is that?
Mimi
Modest. It added 82,483 shares, taking its stake to 892,859, about 1.40% of the company and roughly $21.4 million at quarter-end.
Luke
And that's a snapshot. The 13F covers the first quarter. It doesn't tell us what Deutsche Bank has done since.
Mark
Other institutions were buying too, weren't they?
Mimi
Yes. CalSTRS, Ameriprise, BNY Mellon and Rhumbline all increased holdings, and HSBC opened a new position. Some of those were fourth-quarter moves.
Luke
Worth noting those are small positions next to Deutsche's. The source doesn't give a reason for any of the purchases.
Mark
The stock is far below its high, though.
Mimi
It opened at $21.97 against a $51.61 high, and the latest quarterly loss of $1.20 per share missed the $0.82 consensus.
Luke
The $63 consensus target is an aggregator's figure, and JPMorgan actually lowered its target to $53. The picture is mixed.
Mark
What about the director's purchase?
Mimi
Patrick Enright bought 40,607 shares at $22.35 in June, about $907,566.
Luke
That's a fact, but what it signals about his view is interpretation. The filing doesn't say why he bought.
Le Pouls
- Deutsche Bank lifted its Vera Therapeutics stake by 10.2% to roughly 892,859 shares, a quiet signal of conviction in a turbulent stock.
- Shares trade near $21.97, far below a one-year high of $51.61, leaving holders staring at steep paper losses.
- Quarterly results missed expectations, with a loss of $1.20 per share against a forecast of $0.82, rattling the story's confidence.
- Several institutions and insiders have been buying alongside the bank, suggesting a tug-of-war between doubt and belief.
- Analysts still lean toward a Moderate Buy with a $63.00 average target, but the next round of filings will show whether the buying persists.
A large European bank has quietly added to its stake in a young biotechnology company, a small but telling move made at a moment when that company's shares have fallen far from their peak. Deutsche Bank's purchase of more than eighty thousand shares in the first quarter, disclosed through a routine regulatory filing, sits among similar accumulations by pension funds, asset managers and other institutions, even as the stock trades near twenty-two dollars and recent earnings came in worse than expected. The picture is one of patient capital weighing a long scientific bet against a discouraging short-term present, and the filing itself captures only where that patience stood months ago.
Deutsche Bank added 82,483 shares of Vera Therapeutics during the first quarter, according to its latest 13F filing with the Securities and Exchange Commission. The position now stands at 892,859 shares, about 1.40 percent of the company, a rise of 10.2 percent.
The bank was not alone. Pension systems, asset managers and other banks have also increased or opened positions, and institutions together hold more than 99 percent of the stock. Insiders have been buyers too, with a director purchasing over forty thousand shares in June.
The stock has struggled. It opened at $21.97, well below its one-year high of $51.61, and its latest quarterly loss of $1.20 per share fell short of the expected $0.82 loss. Analysts remain mostly positive, with a consensus rating of Moderate Buy and an average target of $63.00, though some have trimmed their targets.
Vera is a clinical-stage biotech developing treatments for serious immune diseases, led by atacicept, an injectable drug now in Phase III trials for a kidney condition. The filing reflects the bank's position at the end of March, not today, so the next round of disclosures will reveal whether this buying continues.
Deutsche Bank AG added 82,483 shares of Vera Therapeutics (NASDAQ:VERA) during the first quarter, according to its latest 13F filing with the Securities and Exchange Commission. The purchase raised its position by 10.2%, to 892,859 shares. That works out to about 1.40% of the company, worth $21,446,000 at the end of the quarter.
Deutsche Bank was not the only institution moving. California State Teachers Retirement System raised its holding by 19.9% in the fourth quarter, buying 6,749 shares, and now owns 40,640 shares valued at $1,719,000. Ameriprise Financial grew its stake by 31.7% in the same quarter, adding 7,227 shares for a total of 30,021, worth $1,270,000. Bank of New York Mellon added 1,717 shares in the first quarter, a 1.2% increase, bringing it to 143,665 shares valued at $3,451,000. Rhumbline Advisers increased its position by 7.9%, buying 4,600 shares, and holds 63,189 shares worth $1,518,000. HSBC Holdings opened a new position in the fourth quarter valued at roughly $264,000. Institutions as a group own 99.21% of the stock.
The stock itself has had a rough stretch. VERA opened at $21.97 on Thursday, against a one-year range of $18.53 to $51.61. Its fifty-day moving average is $22.34 and its 200-day average is $24.88. The market capitalization is $1.40 billion. The balance sheet shows a debt-to-equity ratio of 0.16 and a current and quick ratio of 17.03.
The most recent earnings report came on Tuesday, August 5th. Vera posted a loss of $1.20 per share, against a consensus estimate of a $0.82 loss, a miss of $0.38. A year earlier the loss was $0.62 per share. Analysts expect a loss of $2.89 per share for the full fiscal year.
Analyst opinion has been mostly positive but uneven. HC Wainwright reaffirmed a buy rating on June 2nd and raised its price target from $75 to $85. Scotiabank reiterated outperform and Guggenheim reiterated buy, both on June 3rd. Wolfe Research reissued a peer perform rating on August 4th. JPMorgan Chase kept an overweight rating on August 7th but cut its target from $56 to $53. Across the coverage, two analysts rate the stock a hold, seven a buy, and one a strong buy. MarketBeat.com puts the consensus at Moderate Buy, with an average price target of $63.00.
Insiders have been buyers too. Director Patrick G. Enright bought 40,607 shares on Tuesday, June 24th, at an average of $22.35, for a total of $907,566.45. After the transaction he owned 3,596,593 shares, valued at $80,383,853.55, a 1.14% increase in his holding. Insiders collectively own 16.30% of the company.
Vera is a clinical-stage biotechnology company working on treatments for serious immunological diseases. Its lead candidate is atacicept, a fusion protein that patients self-administer by subcutaneous injection. It is in Phase III trials for immunoglobulin A nephropathy and in Phase II trials for lupus nephritis.
The filing shows where Deutsche Bank stood at the end of March, not where it stands now. Whether other institutions keep adding as the shares trade near $22 is the thing to watch in the next round of 13F filings.
Citations marquantes
Vera Therapeutics presently has a consensus rating of Moderate Buy and a consensus price target of $63.00.— MarketBeat.com, as cited by ETF Daily News
Envie de l'histoire complète ?
Lire l'original sur ETF Daily News ↗
Economy & Finance